Guggenheim raises Adicet Bio stock price target on positive lupus data
PositiveFinancial Markets

Guggenheim has raised its stock price target for Adicet Bio following promising data related to lupus treatment. This is significant as it reflects growing confidence in Adicet's potential to address a challenging autoimmune condition, which could lead to increased investment and interest in the biotech sector. Positive developments like this can boost not only the company's stock but also the overall market sentiment towards innovative therapies.
— Curated by the World Pulse Now AI Editorial System